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March 2017 levels. 13, 14 Our previous studies showed that the miR-17-92 cluster plays an important role in mediating neural progenitor cell function by increasing cell proliferation and inhibiting cell death. 15 Axonal alteration of the miR-17-92 cluster expression contributes to axonal outgrowth of embryonic cortical neurons by locally modulating phosphatase and tensin homolog (PTEN) protein levels. 16 In vitro, the tailored MSC exosomes containing elevated miR-17-92 cluster further enhance axonal growth compared with control MSC exosomes (Exo-Con). 17 Collectively, these studies suggest that tailored MSC exosomes carrying the elevated miR-17-92 cluster enhance stroke recovery.
In the present study, for the first time, we use exosomes engineered with a specific miRNA cluster gene to treat stroke and demonstrate that these tailored exosomes provide an increased therapeutic effect on neurological recovery compared with the functional benefits derived from treatment with naive exosomes. Intravenously (IV) administered tailored MSC exosomes containing elevated miR-17-92 cluster were administered to rats subjected to middle cerebral artery occlusion (MCAO). We investigated the effects of these exosomes on the differential fate of the neural progenitor cells, as well as on the promotion of neurite remodeling, neural plasticity, and subsequently, functional recovery poststroke. We demonstrate that MSC exosomes containing elevated miR-17-92 cluster increase neural differentiation and plasticity and neurological recovery poststroke compared with the Exo-Con. The miR-17-92 cluster regulates PTEN expression and its downstream signaling pathway, which affects phosphorylation of protein kinase B (Akt), mechanistic target of rapamycin (mTOR), and glycogen synthase kinase 3β (GSK-3β), and may underlie the differential therapeutic benefit of miR-17-92 augmented exosomes for stroke.
Materials and Methods
All experimental procedures were performed in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Henry Ford Health System. All persons who performed the experiments, collected data, and assessed outcome were blinded to the treatment allocation throughout the course of the experiments.
Tailored MSC Exosomes Containing Elevated miR-17-92 Cluster
To generate tailored MSC exosomes containing elevated miR-17-92 cluster, an miR-17-92 cluster-contained plasmid (pCAG-GFPmiR-17-92, constructed according to our published protocol 16 ) was transfected by electroporation into primary cultured MSCs isolated from rat bone marrow, with empty pcDNA3.1 expression plasmids (GenScript, Piscataway, NJ) transfection as control. Accordingly, the exosomes generated from the cultured media of those MSCs are referred to as miR-17-92 cluster-elevated MSC exosome (ExomiR-17-92 + ) and Exo-Con, respectively. See methods in the onlineonly Data Supplement.
Exosome Isolation and Quantification
Exosome isolation from the cell-cultured media was performed at 4°C via multistep centrifugation, as previously described. 7, 8 See methods in the online-only Data Supplement.
MCAO Model, Exosome Treatment, and Behavioral Tests
Adult male Wistar rats (weighing 270-300 g) purchased from Charles River (Wilmington, MA) were subjected to 2 hours MCAO, using a method of intraluminal vascular occlusion, as modified in our laboratory. 4, 18 Exo-miR-17-92 + or Exo-Con dissolved into 0.5 mL phosphate-buffered solution were IV administered to the rats (100 μg total exosome protein per rat, respectively) at 24 hours after induction of stroke. Rats subjected to MCAO treated with 0.5 mL phosphate-buffered solution-diluted synthetic liposomes (3×10 11 particles, which is comparable to the particle number of 100 μg total protein exosomes, as determined in our laboratory.) were used as vehicle control (n=8/group, respectively). To mimic the MSC exosomal lipid layer, we prepared liposomes consisting of the 3 primary fatty acids that we identified in MSC exosomal lipid analysis via the thin-film hydration technique (see methods in the online-only Data Supplement). 19 To label cell proliferation, rats received intraperitoneal injections of the 5-bromodeoxyuridine (BrdU; 50 mg/kg) daily starting 24 hours after MCAO for 14 days.
A modified neurological severity score and Foot-fault tests were performed by a blinded investigator before MCAO and at 1, 3, 7, 14, 21, and 28 days after MCAO, as previously described. 20 All rats were euthanized at 28 days post-MCAO. Randomly selected 5 rat brains per group were snap frozen in liquid nitrogen after saline perfusion, and the frozen coronal sections were cut (40 μm thickness for molecular studies, eg, Western blot, 8 μm thickness for immunohistochemical staining) and stored in −80°C for later analysis. The remaining 3 rat brains per group were removed and rinsed with distilled water after saline perfusion, followed by Golgi-Cox staining.
Histochemistry and Immunohistochemistry
Bielschowsky silver combined with Luxol fast blue histochemistry staining as well as immunostaining with antibodies against the phosphorylated epitope of neurofilament heavy polypeptide (NF-H) and synaptophysin were used, respectively. To detect neurogenesis and oligodendrogenesis in the IBZ, we double stained the specific differentiation markers of neurons and progenitor and mature oligodendrocytes with BrdU. See methods in the onlineonly Data Supplement.
Golgi-Cox Staining
To investigate the changes of neuronal dendrites and dendritic spines in the ischemic brain after treatment, a Golgi-Cox impregnationbased FD Rapid GolgiStain Kit (PK401; FD Neuro-Technologies, Inc, Columbia, MD) was used to stain the neurons and glia following the manufacturer's protocol with modifications in our laboratory. 21 See methods in the online-only Data Supplement.
Western Blot Assay
To detect PTEN expression and subsequent activation of PTEN downstream proteins, Akt, and mTOR, as well as inhibition of GSK-3β activity, the total protein extracted from the IBZ area of frozen brain section was used for Western blot assay following the standard protocol (Molecular Clone, Edition II). See methods in the onlineonly Data Supplement.
Statistical Analysis
Data are summarized and presented using mean±standard error (SE). The differences between mean values were evaluated with the 1-way analysis of variance (ANOVA) and Dunnett's post hoc test. The Global test using the Generalized Estimating Equation was used to evaluate the MSC exosome treatment effects influenced by miR17-92 cluster enrichment on functional recovery. 22 All statistical analyses were conducted using SAS software (version 9.2; SAS Institute, Cary, NC).
Results

MiR-17-92 Cluster-Elevated MSC Exosomes Improve Neurological Outcome After Stroke
We used a single harvest of miR-17-92 exosomes for the treatment of all animals. Real-time reverse transcriptase polymerase chain reaction analysis with TaqMan miRNA assay kit revealed that levels of individual members of the miR-17-92 cluster in exosomes harvested from MSCs transfected by the miR-17-92 vector were increased compared with miRNAs in exosomes harvested from MSCs transfected by an empty vector (7.4-folds of miR-17, 1.3-folds of miR-18a, 3.6-folds of miR-19a, 4.8-folds of miR-19b, 29.2-folds of miR-20a, and 3.0-folds of miR-92, respectively).
Compared with the liposome treatment, both exosome treatment groups exhibited significant reduction in neurological deficits in the modified neurological severity score test ( Figure 1A ) and Foot-fault test ( Figure 1B ). Significant improvement in neurological function was detected 7 days after MCAO in the Exo-miR- + and in the Exo-Con treatment groups on the modified neurological severity score test; however, for the Foot-fault test, significant improvement was apparent 7 days and 21 days after MCAO in the ExomiR- + and in the Exo-Con treatment groups, respectively. Compared with the Exo-Con, the Exo-miR-17-92 + treatment significantly increased functional improvement, indicated by modified neurological severity score test (P<0.05 after day 21; Figure 1A ) and Foot-fault test results (P<0.05 after day 14; Figure 1B ).
MiR-17-92 Cluster-Elevated MSC Exosomes Increase Neurite Remodeling in the IBZ
To identify the histological basis underlying the enhanced functional recovery of tailored MSC exosomes containing elevated miR-17-92 cluster, we used a set of methods to assess dendritic, axonal, synaptic, and myelin remodeling. To evaluate the axon-myelin bundles in the white matter in the IBZ, Bielshowsky silver and Luxol fast blue were used for detecting axons and myelin, respectively. Our data show that the exosome treatment significantly increased axon-myelin bundle density along the IBZ compared with the liposome control 28 days after MCAO (Figure 2A ; P<0.05, respectively), whereas Exo-miR-17-92 + further increased the axonal density compared with the Exo-Con (Figure 2A ; P<0.05).
Immunohistochemistry staining with antiphosphorylated NF-H (p-NF-H) antibody identifies the accumulation of p-NF-H in axons and dendrites after stroke and reflects the axonal plasticity in the peri-infarct region. Our data show that the exosome treatment significantly increased the p-NF-H immunoreactive area in the IBZ compared with the liposome treatment 28 days after MCAO ( Figure 2B ; P<0.05, respectively), and similarly, Exo-miR- + further increased the p-NF-H immunoreactivity compared with the Exo-Con ( Figure 2B ; P<0.05).
To measure synaptic plasticity, synaptophysin was stained by immunohistochemistry. Immunostaining data show that compared with the liposome treatment group, the MSC exosome treatment significantly increased synaptophysin immunoreactivity in the IBZ 28 days after MCAO ( Figure 2C ; P<0.05, respectively), while Exo-miR-17-92 + further increased the synaptophysin immunoreactivity compared with the ExoCon ( Figure 2C ; P<0.05).
MiR-17-92 Cluster-Elevated MSC Exosomes Increase Neuronal Dendritic Plasticity
Dendrites and dendritic spines provide support for axonal outgrowth, 23 and axonal outgrowth accompanied with dendritic plasticity is present in the cortical peri-infarct area after experimental stroke. 21 We analyzed dendritic plasticity by means of Golgi silver impregnation and found that compared with liposome treatment, the exosome treatment significantly increased primary and secondary neurite branching as well as spine density, and Exo-miR-17-92 + further increased dendritic plasticity compared with the Exo-Con (Figure 3B through 3D ; P<0.05, respectively).
MiR-17-92 Cluster-Elevated MSC Exosomes Increase Neurogenesis and Oligodendrogenesis in the IBZ
The miR-17-92 cluster increases neural progenitor cell proliferation and reduces neural progenitor cell death 15 and regulates oligodendrogenesis during development. 24 Our present data show that newly generated neurons (identified by cells Figure 5A-1) and increased the phosphorylation of Akt (Figure 5A -2) and mTOR ( Figure 5A-3 ) and the phosphorylation of GSK-3β ( Figure 5A-4) . Double immunofluorescence staining shows that p-GSK-3β was localized in the IBZ neurons ( Figure 5B ). Because GSK-3β inhibits axonal outgrowth and phosphorylation of GSK-3β inactivates its function, our data suggest that Exo-miR-17-92 + treatment targets PTEN and subsequent activation of the downstream PI3K/Akt/mTOR signaling pathway to inactivate GSK-3β in neurons.
Discussion
MSC exosomes are hypothesized as the major paracrine effectors of MSCs because they are involved in cell-to-cell communication by encapsulating and transferring a large number of functional factors, including regulatory RNAs, proteins, or lipids, 6, 10, 11 to the recipient cells. In our previous studies, we found that MSC-generated exosomes mediate therapeutic benefits of MSC therapy for stroke, 7 and the therapeutic impact of MSC exosomes may be attributed in part to their miRNA contents. 6, 8 Functional benefits derived from MSC treatment of stroke may also, in part, be attributed to the induction of the sonic hedgehog pathway in brain parenchymal cells, 27 and we and others have demonstrated that sonic hedgehog stimulates the miR-17-92 cluster. 15, 28 Based on our in vitro data that overexpression of the miR-17-92 cluster promotes axonal outgrowth of primary cortical neurons cultured in a microfluidic chamber, 16 and the important role of the miR-17-92 cluster in mediating neural progenitor cell function, including cell proliferation and cell death, 15 we selected the miR-17-92 cluster as a target for our studies of using tailored exosomes with modified miRNA content for the promotion of brain plasticity and enhancing functional recovery from stroke. Our in vitro studies then demonstrated the tailored MSC exosomes containing elevated miR-17-92 cluster further enhances axonal growth compared with native MSC exosomes. 17 Here, our in vivo study demonstrates for the first time that MSC-harvested exosomes engineered to elevate the miR-17-92 cluster augment the Exo-Con-mediated improvement of neurological outcome for stroke recovery and increase neural remodeling, including neurogenesis, oligodendrogenesis, and neurite plasticity. Because frozen sections of the cerebral tissue were obtained and primarily used for specific Western blot and histological analyses, H&E staining for analysis of volume of cerebral infarction was not performed in the present study. Although we and others have demonstrated that volumes of cerebral infarction are not altered by the MSC and MSC exosome treatments when treatment was initiated 24 hours poststroke, 7, 29, 30 we cannot exclude the possibility that treatment with miR-17-92-enriched MSC exosomes at 24 hours poststroke also evokes some neuroprotective benefits in the ischemic boundary region.
In the present study, we found that the miR-17-92 members increased in the MSC exosomes after transfection, and our previous studies have demonstrated that miRNA content in the MSC exosome transferred to recipient cells in vitro and in vivo. 8, 9, 17, 31 Also, we have found that a validated miR-17-92 target, PTEN, was downregulated in the brain tissue, which suggests that the miR-17-92 cluster members transferred to cerebral tissue after treatment with the miR-17-92-enriched MSC exosomes and, thereby, contributed to recovery. The increase of miR-17-92 cluster level in MSCs may alter profiles of the proteins, lipids, and the RNAs in the MSCs, as well as their exosome cargos. We also do not exclude the possibility that enriching the exosome miR-17-92 cluster likely alters the myriad of protein/RNA/lipid content of exosomes, and secondary changes in exosome content induced by introducing of miR-17-92 may contribute to the enhancement of plasticity and neurological recovery post stroke, possibly, via direct modification of the recipient cells or indirectly by affecting 
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March 2017 recipient cell targeting or uptake. However, it is evident that the enrichment of the miR-17-92 cluster as a perturbation to the complex web of exosome cargo facilitates recovery, given that PTEN, a major target of the miR-17-92, is concomitantly altered with miR-17-92. The importance of our current study is that it demonstrates, for the first time, that tailoring the exosome content with targeted miRNAs may be a viable option to promote restorative neurological processes after stroke. Investigation of the contributions of secondary changes of (possibly hundreds of) proteins, lipids, and RNAs as a result of selectively enriching the miR-17-92 cluster is warranted. Exosome therapy, by minimizing potential adverse effects of administering potentially replicating and thrombosis-mediating cells, 32 provides a novel treatment for stroke, with the possibility to replace cell-based therapy. 6, 33, 34 We have previously demonstrated that exosomes harvested from cells likely provide the therapeutic effects of cell-based therapies. 7, 35 However, the complexities and questions associated with therapeutic action present in cell-based therapy are also evident in exosome therapy, for example, the distribution, localization, and half-life of administered exogenous exosomes, as well as questions of potential systemic and immune/inflammatory system modulating effects. Exosomes penetrate the bloodbrain barrier 36, 37 ; however, the detailed mechanisms of doing so are unclear. Given the difficulty in measurements, the cellular and organ distribution of the IV-administered exosomes were not determined in the current study. It is likely, as with the use of cell-based therapies, that most of the exosomes are distributed in other organs, like the liver. 38, 39 However, given that the molecular target of the miR-17-92 in brain, that is, PTEN, responds to the exosome administration, it is likely that exosomes do enter brain. We do not exclude the possibility that like cell-based therapies, exosome therapy modulates the immune/inflammatory system, which in concert with the induction of neuroplasticity or independently contributes to the therapeutic efficacy. Investigation of the exosome contributions to systemic effects and the modulation of immune/ inflammatory system by enriching the miR-17-92 cluster in exosomes is warranted. Although angiogenesis after ischemic stroke correlates with improvement of functional outcome in both animal models and in human patients with stroke, 40 our previous data show that treatment with naïve MSC exosomes increases angiogenesis 7 ; in the current study, we did not observe angiogenesis induced by Exo-miR-17-92 + . A possible explanation is that individual members of the miR-17-92 cluster are either proangiogenic or antiangiogenic, and the net effect of the cluster may be context dependent. 41, 42 Thus, with the miR-17-92 enrichment, there is a balanced proangiogenic or antiangiogenic effect, which may mitigate the net induction of angiogenesis.
Our present study only focused on the miR-17-92 cluster targeting the PTEN signaling pathway because PTEN is a validated target of miR-17-92 cluster and the miR-17-92/PTEN axis controls neurite remodeling, 16, 25 cell proliferation, and differentiation. 15, 26 Our previous in vitro data demonstrated that overexpression of the miR-17-92 cluster promoted axonal outgrowth of primary cortical neurons cultured in a microfluidic chamber, via downregulating of PTEN and subsequent activation of the PI3K/Akt/mTOR signaling pathway. 16 In vivo, stroke induces limited axonal outgrowth in the peri-infarct region, which was closely associated with an increase in myelin proteins. 24 The miR-17-92 cluster also regulates oligodendrogenesis during development 24 and promotes stroke-induced neurogenesis. The PTEN/PI3K/mTOR signaling pathway mediates axonal regeneration after spinal cord injury. 43 GSK-3β plays an essential role in axon regeneration, 44 and inactivation of GSK-3β promotes axonal growth and recovery in the central nervous system. 45 Expression of PTEN and activation of its downstream proteins, Akt, mTOR, and GSK-3β in the peri-infarct region were measured by means of Western blots and immunohistochemistry. We found that exosomes encapsulating the elevated miR-17-92 cluster downregulated PTEN, as well as activated the PTEN downstream proteins, Akt, and mTOR and inhibited GSK-3β activity by increasing the phosphorylation of GSK-3β, the inactivated form of GSK-3β. Further studies on the quantification of mRNA levels of PTEN in neurons, and connective tissue growth factor and Tsp1 in astrocytes, are warranted.
Summary
We demonstrate, for the first time, that IV treatment of stroke with exosomes tailored to encapsulate an increase of a specific miRNA cluster gene, the miR-17-92 cluster, significantly increases neurogenesis, oligodendrogenesis, and neural plasticity and significantly augments the therapeutic benefits for stroke treated with control exosomes. The molecular bases for these restorative changes may in part be attributed to the miR-17-92 cluster downregulation of PTEN expression and subsequent activation of PTEN downstream proteins, Akt, and mTOR, as well as inhibition of GSK-3β activity. This study demonstrates that stroke may be treated with exosomes whose content is engineered to amplify neural plasticity and enhance functional recovery. This novel therapeutic approach may find application for other forms of neural injury or disease.
